Skip to main content
. 2022 Oct 28;12:1029960. doi: 10.3389/fonc.2022.1029960

Table 1.

Clinical characteristics of the clinical trial and real-world cohort.

Characteristics Clinical trial cohort (n = 45) n(%) Real-world cohort (n = 55) n(%) P-value
Age 0.364
 <60 34 (76) 37 (67)
 ≥60 11 (24) 18 (33)
Sex 0.867
 Male 35 (78) 42 (76)
 Female 10 (22) 13 (24)
ECOG PS 0.001*
 0 35 (78) 25 (45)
 1 10 (22) 25 (45)
 2 0 (0) 5 (9)
Location 0.118
 GEJ 9 (20) 5 (9)
 Non-GEJ 36 (80) 50 (91)
Stage 0.108
 III 8 (18) 4 (7)
 IV 37 (82) 51 (93)
Lauren classification 0.550
 Intestinal type 20 (61) 10 (59)
 Diffused type 6 (18) 5 (29)
 Mixed type 7 (21) 2 (12)
 Unknown 12 38
HER2 expression 0.494*
 Positive 0 (0) 2 (5)
 Negative 39 (100) 40 (95)
 Unknown 6 13
Metastasis site 0.036*
 Liver 22 (49) 24 (44)
 Peritoneal 6 (13) 13 (24)
 Bone 6 (13) 1 (2)
 Pancreas 0 (0) 5 (9)
 Abdominal wall 0 (0) 5 (9)
 Colorectal 1 (2) 2 (4)
 Ovary 1 (2) 2 (4)
 Bladder 2 (4) 1 (2)
 Others 5 (11) 6 (11)
MMR status 0.485*
 pMMR 31 (97) 34 (100)
 dMMR 1 (3) 0 (0)
 Unknown 13 21
PD-L1 expression 1*
 Positive 8 (42) 0 (0)
 Negative 11 (58) 1 (100)
 Unknown 26 54
Differentiation 0.015
 Poor 15 (39) 31 (66)
 Moderate-well 23 (61) 16 (34)
 Unknown 7 8
History of gastric cancer operation 0.110
 Yes 7 (16) 16 (29)
 No 38 (84) 39 (71)
History of smoke 0.099
 Yes 10 (23) 21 (38)
 No 34 (77) 34 (62)
 Unknown 1 0
History of alcohol 0.475
 Yes 10 (23) 16 (29)
 No 34 (77) 39 (71)
 Unknown 1 0

ECOG PS, Eastern Cooperative Oncology Group Performance Status; MMR, proficient mismatch; pMMR, proficient mismatch repair; dMMR, deficient mismatch repair.

*Fisher’s exact probability method.